

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18 **Indium-111 labelling of liposomal HEGF for radionuclide delivery via**  
19 **ultrasound-induced cavitation**  
20

21 Joshua Owen<sup>1</sup>, Eloise Thomas<sup>2</sup>, Jyothi Menon<sup>2</sup>, Michael Gray<sup>1</sup>, Irini Skaripa-Koukelli<sup>2</sup>, Martin  
22 R. Gill<sup>2</sup>, Sheena Wallington<sup>2</sup>, Rebecca L. Miller<sup>2</sup>, Katherine Vallis<sup>\*2</sup> and Robert Carlisle<sup>\*1</sup>.  
23  
24

25 <sup>1</sup> Department of Engineering Science, Institute of Biomedical Engineering, University of  
26 Oxford, Old Road Campus Research Building, Oxford OX3 7DQ

27 <sup>2</sup> CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of  
28 Oxford, Old Road Campus, Oxford, OX3 7DQ

29 <sup>\*</sup>Both authors contributed equally  
30  
31  
32  
33  
34

35 Keywords: ultrasound, nanoparticles, radiotherapy, radiopharmaceuticals, liposomes,  
36 enhanced delivery, cavitation  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## Abstract

The purpose of this exploratory study was to investigate the combination of a radiopharmaceutical, nanoparticles and ultrasound (US) enhanced delivery to develop a clinically viable therapeutic strategy for tumours overexpressing the epidermal growth factor receptor (EGFR). Molecularly targeted radionuclides have great potential for cancer therapy but are sometimes associated with insufficient delivery resulting in sub-cytotoxic amounts of radioactivity being delivered to the tumour. Liposome formulations are currently used in the clinic to reduce the side effects and improve the pharmacokinetic profile of chemotherapeutic drugs. However, in contrast to non-radioactive agents, loading and release of radiotherapeutics from liposomes can be challenging in the clinical setting. US-activated cavitation agents such as microbubbles (MBs) have been used to release therapeutics from liposomes to enhance the distribution/delivery in a target area. In an effort to harness the benefits of these techniques, the development of a liposome loaded radiopharmaceutical construct for enhanced delivery via acoustic cavitation was studied. The liposomal formulation was loaded with peptide, human epidermal growth factor (HEGF), coupled to a chelator for subsequent radiolabelling with  $^{111}\text{Indium}$  ( $[^{111}\text{In}]\text{In}^{3+}$ ), in a manner designed to be compatible with preparation in a radiopharmacy. Liposomes were efficiently radiolabelled (57%) within 1 h with release of ~12% of the radiopeptide following a 20 s exposure to US-mediated cavitation *in vitro*. In clonogenic studies this level of release resulted in cytotoxicity specifically in cells over-expressing the epidermal growth factor receptor (EGFR), with over 99% reduction in colony survival compared to controls. The formulation extended the circulation time and changed the biodistribution compared to the non-liposomal radiopeptide *in vivo*, although interestingly the biodistribution did not resemble that of liposome constructs currently

used in the clinic. Cavitation of MBs co-injected with liposomes into tumours expressing high levels of EGFR resulted in a 2-fold enhancement in tumour uptake within 20 min. However, owing to the poor vascularisation of the tumour model used the same level of uptake was achieved without US after 24 h. By combining acoustic-cavitation-sensitive liposomes with radiopharmaceuticals this research represents a new concept in achieving targeted delivery of radiopharmaceuticals.

## Introduction

Targeted radionuclide therapy (TRT) combines the specificity of tumour seeking carriers with the toxicity of radioisotopes[1]. There are several examples of this approach in clinical use such as <sup>177</sup>Lutetium-Dotatate for neuroendocrine tumours[2], and <sup>177</sup>Lutetium-prostate-specific membrane antigen (PSMA inhibitor) for metastatic castration-resistant prostate cancer[3]. However, both these strategies rely on <sup>177</sup>Lutetium which emits high energy electrons (beta-particles) with a track length in the centimeter range which can lead to off target effects[4]. One promising strategy for TRT is the use of radionuclides that decay through electron capture and the release of short track-length (< 30 µm), moderately high linear energy transfer (LET) electrons that cause very localised damage and few unwanted off-target effects[4]. To cause cancer cell death these radionuclides must enter the nucleus in sufficient quantity to give rise to irreparable DNA damage. The conjugation of such radionuclides to carriers with cell-penetrating and/or nuclear localizing sequences offers a route to enhanced selectivity [4, 5]. A previously tested example of this strategy is the use of [<sup>111</sup>In]In<sup>3+</sup>, which decays through electron capture, tagged to the HEGF peptide ([<sup>111</sup>In]In-HEGF)

which binds to the EGFR that is overexpressed by a range of solid cancers. Crucially, following binding of HEGF, the EGFR translocates to the nucleus, delivering [ $^{111}\text{In}$ ] $\text{In}^{3+}$  to the site where its decay can impact cell survival most effectively[6]. However, a notable limitation of this approach is that the small size of peptide-based radiopharmaceuticals renders them susceptible to rapid renal clearance giving rise to unfavourable circulation kinetics[7]. This can often result in insufficient accumulation of radionuclides within tumours[8]. Also in the case of small peptides reabsorption and retention in the proximal tubules after glomerular filtration can cause a high radiation dose in the kidneys therefore lowering the administered dose for small peptide radiopharmaceuticals is desirable[9]. Molecularly targeted agents such as peptides are also limited by low payloads and insufficient delivery of radioactivity to the tumour[10] as well as causing side effects such as flushing, chills, nausea, and vomiting[11]. EGFR is apparent in some of the most frequent cancers but the benefits of small agents for anti EGFR therapy plus cytotoxic agents have yet to appear[12].

Nanoparticles can be designed for drug delivery and may be fabricated from natural or synthetic compounds[7]. Nanoparticle delivery systems have been shown to reduce the cytotoxicity of low molecular weight chemotherapeutics and provide greater anticancer efficacy[13]. This means dosing need not be limited by the risk of severe adverse effects in non-target tissue[14]. Liposomes are a class of nanoparticle which are particularly suited to cancer therapy as they are easy to produce and can encapsulate a large payload of active therapeutics within the aqueous core of their spherical lipid bilayer. Furthermore, it is possible to surface modify liposomes with polyethylene glycol (PEG)[15] to provide protection from reticuloendothelial system (RES) mediated clearance. Drug encapsulating liposomal formulations can therefore

dramatically extend the blood circulation time compared to free drug. In turn, this may allow passive accumulation and retention in tumours through the enhanced permeability and retention (EPR) effect[16], and although the true extent of the EPR effect is contentious[17] there is pre-clinical and clinical data in support of the improved efficacy it provides. Specifically, Doxil®, which was the first liposome formulation to be approved for clinical use[18, 19] demonstrates a clearance rate in humans of approximately 0.1 L/h, compared to 45 L/h for unencapsulated doxorubicin[18, 20]. Liposomes can be produced by a variety of techniques [21, 22]. Although liposomal formulations are currently available in the clinic for delivery of chemotherapeutics[18], they have not been used clinically for the delivery of radioisotopes.

The application of liposomes to the delivery of radioisotopes therefore appears ripe for exploitation, although, there are key factors limiting the success of such a strategy. Firstly, the timescale of the conventional process of liposome formulation, loading and purification is not always compatible with the timescale and working practice required when using radioisotopes clinically. Most research has focused on decorating the surface of nanoparticles with radiopharmaceuticals [23, 24]. Although, methods to load radioactive compounds and radiopharmaceuticals into liposomes have also been developed previously, these techniques have substantial limitations that must be overcome before achieving clinical translation [23, 25-29]. For example, freeze thaw was used to load <sup>99m</sup>Techetium-ceftizoxime into liposomes. However, the half-life of technetium is 6 h and freeze thaw cycles typically take multiple hours and require techniques and equipment which are not always readily available in a hospital environment[30]. Pre-loading of liposomes with a radioisotope at a manufacturing site would create transport and storage times that would compromise the amount of radioactivity available by the time of use. Methods of encapsulating radioisotopes in a

more clinically viable fashion have been developed via loading of  $^{64}\text{Cu}$ ,  $^{52}\text{Mn}$  and  $^{111}\text{In}^{3+}$  into liposomes[31-33]. Furthermore, most research reported to date, has sought to encapsulate the radioisotope without providing mechanisms for cancer cell targeting, release from the liposome or for trafficking of the radionuclide to the nucleus once release from the liposome has occurred[34]. Therefore, these constructs become entirely dependent on the EPR effect for tumour selectivity, with no means of either releasing the payload from the liposome or ensuring penetration from the perivascular regions into and throughout the tumour mass.

To address the above challenges, we describe a long-term-storage compatible 'platform' liposome loaded with DTPA-HEGF which can be easily post-loaded with  $^{111}\text{In}^{3+}$  just prior to clinical administration. Furthermore, by ensuring the liposome formulation is responsive to US-mediated cavitation events, it is possible to achieve temporal and spatial control of radiopharmaceutical cargo release[14]. Indeed, ultrasound, a longitudinal pressure wave of frequency >20 kilohertz (kHz), can be efficiently delivered through the body and localised to millimetre scale tissue domains when using low Megahertz (MHz) frequencies, exposing them to alternating compression and rarefaction cycles of microsecond duration. These waves can create cavitation events, i.e. the expansion and collapse of a gas bubble from pre-formed cavitation nuclei such as a shelled microbubble, which can be co-delivered with the therapeutic into the blood stream[35]. The mechanical action of such cavitation events can increase the permeability of cell membranes, and/or selectively disrupt the membranes of liposomes[14, 36, 37]. Hence, whilst in conventional drug delivery systems the drug is limited to the perivascular region and transport is controlled by

diffusion[36], US-mediated-cavitation used in combination with cavitation responsive carriers can provide a powerful and safe mechanism to overcome tumour delivery barriers by providing site-specific triggered drug release and enhanced delivery.

In this study, the aim was to determine if a cavitation sensitive liposome loaded with a radiopeptide has clinical potential. We have developed a clinically relevant method of afterloading  $[^{111}\text{In}]\text{InCl}_3$  into cavitation sensitive liposomes for conjugation to encapsulated DTPA-HEGF, a tumour-targeting peptide, for enhanced delivery/triggered release as represented in Figure 1. The methods used at each stage are based on existing techniques, for ease of translation:  $[^{111}\text{In}]\text{In}^{3+}$  labelled HEGF ( $[^{111}\text{In}]\text{In}$ -HEGF) has been tested in humans[11], the liposome formulation is based on those used clinically, and MBs are also currently used in the clinics, although only as US contrast agents to date.




Figure 1, A) *in vivo* schematic of tumour cells adjacent to a blood vessel with cavitation agents and  $[^{111}\text{In}]\text{In-HEGF}$  loaded liposomes and B) application of US induced cavitation to drive liposomes into tumour tissue and to release  $[^{111}\text{In}]\text{In-HEGF}$  to interact with EGFR. Objects shown in the diagram are not drawn to scale, liposomes are 175 nm whereas MBs are 2 – 8  $\mu\text{m}$ .

## Materials and Methods

### Preparation of HEGF

The conjugation of HEGF (Life Sciences, Thermo Scientific, Loughborough, UK) with diethylenetriaminepentaacetic dianhydride 98% (DTPA) (Sigma Aldrich, Gillingham, UK) was carried out as previously described[38]. Briefly, HEGF (1 mg) was dissolved in sodium bicarbonate (pH 8.3) (400  $\mu\text{L}$ ), DTPA (5 x molar excess) was added in DMSO (dimethyl sulfoxide) (30  $\mu\text{L}$ ) and incubated for 45 minutes at room temperature (RT). This solution was then eluted through a Sephadex G25 (Sigma Aldrich, Gillingham, UK) column and the amount of protein recovered in each aliquot (100  $\mu\text{L}$ ) was analysed using a Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE). HEGF was centrifuged (12,300 x g) in a molecular weight cut off (3 kDa)



211 ultrafiltration tube (Amicon®, Sigma Aldrich, Gillingham, UK) three times in 0.1M  
212 citrate buffer (pH 5.0). This was then stored at 4°C for later encapsulation in liposomes.

213

#### 214 *Synthesis of liposomes*

215 All lipids were purchased from Avanti Polar Lipids, Alabaster, Alabama, USA. For the  
216 liposome formulation, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-  
217 tetradecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine (MSPC), 1,2-distearoyl-  
218 sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] DSPE-  
219 PEG(2000) at a molar ratio of (85:5:10) was used resulting in approximately 40 mg of  
220 lipid. The chloroform was removed under high vacuum for 3 h, using a vacuum pump  
221 (Edwards RV12, Edwards, West Sussex, UK) attached to a schlenk line (Glass  
222 Solutions, Watford, UK) via a cold trap (Glass Solutions, Watford, UK) immersed in  
223 liquid nitrogen, to leave a lipid film. Cyclohexane (2 mL) (Sigma Aldrich, Gillingham,  
224 UK) was added to the lipid film followed by vortexing, heating (50°C) for 1 minute,  
225 immersion in liquid nitrogen for 2 min and freeze drying over 2 days (– 50°C and 100  
226 mTorr) (Virtis Lyostar Advantage Plus EL-85) to produce a lipid powder unattached to  
227 the glass. HEGF (see above) (0.5 mg) was reconstituted in citrate buffer (pH 5.0) (200  
228 µL) at a concentration of 10 mg/mL and this was added to the lipid powder. The lipid,  
229 HEGF solution was pipetted up and down using a 100 µL pipette to break up and  
230 disperse the lipids into vesicles. Citrate buffer (0.1 M, 100 µL) was added and the  
231 mixture was extruded 11 times through a 100 nm polycarbonate membrane (Avanti  
232 Polar Lipids, Colorado, USA) at 37°C using a teflon mini-extruder (Avanti Polar Lipids,  
233 Colorado, USA) with 2 syringes (1 mL). The extruded liposomes were then centrifuged  
234 at 12,300 x g for 15 minutes in phosphate buffered saline (PBS) (1 x concentration,  
235 pH 7.1) in a centrifuge tube (Amicon®, Sigma Aldrich, Gillingham, UK) with a

molecular weight cut-off of 30 kDa for a minimum of three cycles to remove any excess non-encapsulated HEGF. Loading efficiency was assessed via High Performance Liquid Chromatography (HPLC) after SE centrifugation and ultracentrifugation (70,000 x g, 30 min) to ensure removal of excess HEGF for accurate analysis of liposome loading [39]. Liposomes were then stored at 4-8°C for later loading with [<sup>111</sup>In]InCl<sub>3</sub>. The liposome size was measured via dynamic light scattering (DLS) (Zetasizer Nano ZS, Malvern Instruments, Worcestershire, UK). Empty Liposomes underwent the same process but without addition of HEGF.

#### *<sup>111</sup>In-Labeling of HEGF loaded liposomes*

HEGF-Lip in PBS (pH 7.5) were incubated with [<sup>111</sup>In]InCl<sub>3</sub> (15 MBq) for 1 h at 38°C, following which the [<sup>111</sup>In]In-HEGF-Lip were separated from free [<sup>111</sup>In]In<sup>3+</sup> by two repeats of size exclusion centrifugation (MW cut off 30 kDa, 12,300 x g for 20 min) (SE centrifugation). A CRC®-25R dose calibrator (Capintec, Inc, Florham Park, NJ) was used to measure the amount of radioactivity present in the filtrates and the collected liposomes. From mixing the HEGF liposome with [<sup>111</sup>In]InCl<sub>3</sub> to obtaining the purified radiolabelled formulation took 2 h.

#### *Characterization of radiolabelled liposomes*

To determine <sup>111</sup>In-labelling efficiency three samples were compared: 1) Empty Liposomes containing no HEGF, 2) non-purified liposomes: i.e. HEGF encapsulated within liposomes and HEGF in the solution outside the liposomes and 3) purified liposomes which had HEGF encapsulated within liposomes only. These three

samples were loaded with [ $^{111}\text{In}$ ]InCl<sub>3</sub> and cleaned twice using SE Centrifugation (MW cut off 30 kDa, 12,300 x g for 20 min). The amount of associated radioactivity in the filtrates and liposome solutions was then compared using the CRC®-25R dose calibrator.

The radiochemical yield was determined by silica gel instant thin-layer chromatography (SG-ITLC) in 0.1 M sodium citrate buffer (pH 5.2). Radioactivity measurements of the silica strips were obtained using radio-TLC scanner (Eckert & Ziegler Radiopharma, Inc., Hopkinton, MA, USA).

#### *Transmission electron microscopy*

Liposome morphology was observed by placing an aliquot of the liposome solution (10  $\mu\text{L}$ ) on a 200-mesh Formvar-coated copper grid (Agar Scientific, Stansted, Essex), allowing it to air-dry and then negatively staining the sample with 2% w/v uranyl acetate and allowing further air drying. A transmission electron microscope (Tecnai T12, FEI, Hillsboro, OR) was used for image acquisition.

#### *Dynamic light scattering (DLS)*

The hydrodynamic diameter of liposomes was measured using DLS (ZetaSizer Nano, Malvern Instruments Ltd, Malvern, Worcestershire, UK). Liposome samples (10  $\mu\text{L}$ ) were added to 990  $\mu\text{L}$  of PBS and each sample measured three times.

#### *Reverse phase chromatography of liposome extracted HEGF*

To determine the uptake of HEGF into liposomes, HEGF standard samples (1  $\mu\text{g}$ , 10  $\mu\text{g}$  and 40  $\mu\text{g}$ ) and HEGF-containing liposomes (HEGF-lip) were separated using a

C18 reverse phase (Supelco) column on a Shimadzu SPD 10A HPLC system (Shimadzu). All samples were suspended in 7% triton X-100 (Sigma Aldrich, Gillingham, UK) and incubated for 20 min, before buffer A (water with 0.1% formic acid) was added to give a final volume of 700 µL. Samples were centrifuged at 12,300 x g for 20 min, the supernatant was then loaded onto a C18 column in buffer A and eluted from the column using eluent B (80% acetonitrile with 0.1% formic acid) on a gradient of 0-50% B in A over 20 min. DTPA-HEGF was monitored at an absorbance of 214 nm. Loading efficiency was determined using the following equation:

$$1) \quad \text{Loading Efficiency (\%)} = \left( \frac{\text{HEGF in Liposome } (\mu\text{g})}{\text{HEGF stock } (\mu\text{g})} \right) \times 100$$

### *Clonogenic assays*

*In vitro* experiments were conducted on EGFR-high MDA-MB-468 ( $1.3 \times 10^6$  EGFR/cell) and EGFR-low MCF7 ( $1 \times 10^4$  EGFR/cell) cells cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin-glutamine (PSG). Cells were seeded in 35 mm, high µ-Dishes with a glass bottom (ibidi GmbH, Am Klopferspitz, Planegg/Martinsried) at a concentration of  $2.5 \times 10^5$  cells/well in 2 mL of supplemented DMEM. These cells were left overnight to attach. The µ-Dishes were examined via light-field microscopy to determine cell attachment, the media was removed, 8 mL of supplemented DMEM was added and cells were exposed to combinations of [ $^{111}\text{In}$ ]In-HEGF loaded liposomes ([ $^{111}\text{In}$ ]In-HEGF-Lip) (1 MBq) and SonoVue™ MBs (200µL) (sulphur hexafluoride microbubbles: Bracco Diagnostics Inc, Milan, Italy) (SV) to give a final

microbubble concentration of  $3.75 \times 10^6$  bubbles/mL, prior to US exposure as outlined in Table 1 below. A test group exposed to US in the absence of a MB agent (i.e. no cavitation) and the presence of [ $^{111}\text{In}$ ]In-HEGF-Lip was not included here because previous studies with US alone with this formulation had shown it to provide no release unless cavitation was instigated[14]. See Supplementary Figures 1 and 2 and Supplementary Information (*ultrasound system characterization*) for US details and characterisation. Cells were incubated for 24 h in the same medium, washed twice with PBS, detached with Trypsin-EDTA (0.05%), phenol red (1 mL) (Thermo Scientific, Loughborough, UK) and seeded in a 6-well plate at multiple seeding densities (500, 1000 and 2000 cells/ well). After 14 days, colonies were fixed and stained using 1% methylene blue mixture in methanol. Colonies were counted using a GelCount automated colony counter (Oxford Optronix, Oxford, UK).

*Table 1, Samples used in clonogenic assays*

Sample Name	Cavitation agent	Ultrasound	Liposomes containing [ $^{111}\text{In}$ ]In-HEGF
Untreated			
US only		X	
MBs only	X		
MBs + US	X	X	
MBs + ([ $^{111}\text{In}$ ]In-HEGF-Lip)	X		X
MBs + ([ $^{111}\text{In}$ ]In-HEGF-Lip)+ US	X	X	X

#### *Liposomal release in response to ultrasound*

Liposomes were exposed to US as described in the Supplementary Information. [ $^{111}\text{In}$ ]In-HEGF-Lip (5 MBq) were added to sealed plates with SV (1 mL) and exposed

to US or a sham exposure at the same conditions as the clonogenic assays. After 2 h, 1 mL of the sample was removed and centrifuged in a molecular weight cut off (30 kDa) SE centrifuge tube (12,300 x g, 20 min) and the total percentage of radioactivity in the filtrate was measured via a CRC®-25R dose calibrator (Capintec, Inc, Florham Park, NJ). The quantity of radioactivity that passed through the filters owing to liposome destruction in the SE centrifugation process was also measured and removed from the results.

#### *Cellular internalisation of radioactivity*

MDA-MB-468 or MCF7 cells were prepared in Ibidi dishes in a similar manner to the clonogenic assays. Cells were exposed to [<sup>111</sup>In]In-HEGF-Lip alone (1 MBq), SV alone (200 µL) or [<sup>111</sup>In]In-HEGF-Lip (1 MBq) and SV (200 µL) with US. After 2 h the cells were washed and trypsinised and the amount of radioactivity measured using a gamma counter (HIDEX, Lemminkäisenkatu 62 FIN-20520 Turku, Finland). To consider cell concentration the protein content of the cells was then measured using the Bincinchoninic acid assay as per manufacturer's instructions (Pierce™ BCA Protein Assay Kit, Thermo Fisher Scientific, MA, USA).

#### *Ethical statement*

All procedures were conducted in accordance with the Animals Scientific Procedures Act of 1986 (UK) (Project License Numbers 30/3115 and P13B66CD9 issued by the Home Office). The protocols were approved by the Committee on the Ethics of Animal Experiments of the University of Oxford. All imaging was performed under 2–4% isoflurane anaesthesia delivered in oxygen enhanced room air (4% for induction of anaesthesia, ~2% for anaesthesia maintenance). Throughout imaging experiments,

mice were maintained at 35-37°C, respiration rate was monitored and all efforts were made to minimize suffering. Mice were housed (5 to 6 animals per cage) in individual ventilated polycarbonate solid-bottomed cages. Airflow within the cages was on a positive pressure and was controlled electronically by an IVC air handling system (Techniplast UK). A 12 h dark and light cycle was implemented with the ambient air temperature set at 21°C +/-2 with 55% +/-10 humidity. All animals were provided with certified rodent diet, filtered water *ad libitum*, autoclaved bedding, nesting material and cage enrichment.

#### *Animal preparation*

Two mouse strains were used to complete the *in vivo* experiments. Athymic nude (NU(NCr)-Foxn1nu), and Severe Combined Immunodeficiency Disease (SCID) (CB17/lcr-Prkdc<sup>scid</sup>/lcrIcoCrI). Athymic nude and SCID mice were selected for their immunodeficient status and ability to support growth of human tumour cells. All mice were adult females, gender was selected based on the use of a breast cancer model. Mice entered study at approximately 40 days old. The mean start weight of athymic nude mice and SCID mice was 25 g and 16 g respectively. SCID mice were used for blood lifetime studies owing to their genetic similarity to athymic nudes and smaller size for use in the required SPECT imaging cradle.

All cancer cells were implanted subcutaneously into the right flank of the mice. MDA-MB-468 were injected at ~5 million cells/site with 50% matrigel (Thermo Scientific, Loughborough, UK) in serum free DMEM. MCF7 cells were not used *in vivo* due to animal welfare considerations owing to their requirement for estrogen supplementation. Where an indwelling cannula was used to administer contrast

agents and treatments, a catheter (PE10, 0.28/0.64 mm internal/external diameter; Linton Instrumentation) was inserted into the lateral tail vein. Omniscan (gadodiamide, 0.5 M, 30  $\mu$ L; GE Healthcare) was used as the contrast agent for Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI), and SonoVue™ (8  $\mu$ L) was used for contrast imaging. All injections were performed manually except for injection of contrast agent for DCE-MRI where a syringe pump was used.

#### *In vivo biodistribution*

Athymic nude mice (6 weeks old) were anaesthetised (4% Isoflurane in air induction followed by 2% for maintenance). Animals were entered into a study when xenograft volume reached 70-100 mm<sup>3</sup>. Mice (4 per group) received either [<sup>111</sup>In]In-HEGF-Lip (6 MBq) or free [<sup>111</sup>In]In-HEGF (6 MBq) via intravenous (i.v.) injection into the lateral tail vein. In both cases the volume of the injectate was 100  $\mu$ L, with equal mass amounts of HEGF administered which was determined using HPLC. Mice were euthanised at 24 h. Xenografts and organs were harvested, weighed and the amount of radioactivity counted using a HIDEX automatic gamma counter (HIDEX, Lemminkäisenkatu 62 FIN-20520 Turku, Finland).

#### *Blood circulation time*

SCID mice (3 per group) were anaesthetised and received either [<sup>111</sup>In]In-HEGF-Lip (6 MBq) or free [<sup>111</sup>In]In-HEGF (6 MBq) i.v. by cannula followed by a saline flush of approximately 20  $\mu$ L to account for the dead volume in the length of the cannula. Animals were placed in a bespoke mouse cradle fitted to a VECTOR 4 CT scanner (MI-Labs, Heidelberglaan, Utrecht, The Netherlands) and their temperature was maintained at 37°C using a thermostatic heating plate and monitoring via a rectal



probe. Dynamic single photon emission tomography (SPECT) images were acquired (1 frame every 36 s for 2 h) centred on the heart. A CT scan was acquired for anatomical information. See Supplementary Information for more details. Animals were euthanised at the end of the imaging procedure. Images were reconstructed via MI-Labs software and the signal due to [ $^{111}\text{In}$ ]In $^{3+}$  in the heart over time was analysed via PMOD software (PMOD Technologies LLC, Sumatrastrasse 25, CH-8006 Zurich, Switzerland).

#### *Tumour uptake of radioactivity*

Tumour uptake was determined at 24 h via organ harvesting as outlined above. For US enhanced delivery this was examined at 20 min via SPECT imaging as outlined above except acquiring 2 frames over 5 min in the area of the tumour and excluding the other areas of the body. The use of this 20 min time point allowed cavitation mediated uptake to be distinguished from EPR mediated uptake which may have been evident at 24 h. The images were quantified in PMOD. The average amount of radioactivity within the tumour or an organ was obtained from mean pixel values within the ROI volume. Assuming a tissue density of 1 g/mL, the ROIs were converted to MBq per gram and were then divided by the total administered activity to obtain the imaging ROI-derived percentage administered activity per gram of tissue (%ID/g).

#### *Focused ultrasound in vivo*

Mice (3 per group) received either [ $^{111}\text{In}$ ]In-HEGF-Lip (6 MBq) i.v. followed by SV (50  $\mu\text{L}$ ) or [ $^{111}\text{In}$ ]In-HEGF-Lip (6 MBq) followed by SV (50  $\mu\text{L}$ ) as well as tumour targeted US. The total injection time for the combined treatment of liposomes and SV was 90  $\pm$  20 s. US (1 MHz, 1 MPa, 30% duty cycle, 10 ms pulse period) was applied to tumours


for 5 min. US was applied after injection of SV was completed. Tumours were treated when they reached an approximate volume of 70 – 100 mm<sup>3</sup>. A mouse was placed on an acoustically transparent mylar bed above a water bath thermostatically controlled at 37°C. A 1.0 MHz center frequency US source was positioned in the water directly underneath the animal (Supplementary Figure 3). The focus of the source was aligned to a spot marked on the mylar bed where the target tumour would be placed. The center of the transducer housed a 7.5 MHz US transducer (Panametrics V320-SU-F 1.75PTF, Olympus NDT, Essex, UK) that was used as a passive cavitation detector (PCD). Receiver signals were high-pass filtered (F5081-2P0, Allen Avionics, Mineola, NY, USA), preamplified (SR445A, SRS, Sunnyvale, CA, USA), digitized (Handyscope HS3, TiePie Engineering, Netherlands) and streamed to a laptop computer disk. For analysis of cavitation activity, PCD time series data sets were processed in Matlab (Mathworks, Natick, MA, USA) using Welch's method for power spectrum calculation, implemented with temporal windows of 80 µs (2.5% of typical source drive pulse length) with 50% window overlap. Before therapy was started, a small amount of centrifuged US coupling gel (Aquasonic 100, Parker Laboratories, Fairfield, NJ) was applied to the mylar at the mark where the tumour would be placed. Centrifuging the coupling gel ensured no air bubbles were present.

## Results and Discussion

### *Liposome characterisation*

Liposome modal diameter, as assessed by DLS (Supplementary Figure 4A, B), was found to be 175 nm with a polydispersity index of 0.15. Transmission electron

microscopy images were in accordance with this size range, with a spherical shaped lipid shell evident, as shown in Figure 2A. Similar size and polydispersity readings were obtained for all liposome formulations, regardless of the presence or absence of HEGF or  $[^{111}\text{In}]\text{In}^{3+}$  (supplementary Figure 4C).



*Figure 2, Characterisation of liposomes. A) Transmission electron microscopy confirming the size and showing the morphology of the HEGF-Lip (scale bar = 100  $\mu\text{m}$ ). B) High Performance Liquid Chromatography analysis of HEGF, Empty Liposomes and HEGF-Lip cleaned by ultracentrifugation. C)  $^{111}\text{In}$ -labelling efficiency of empty liposomes compared to liposomes containing HEGF, after addition of  $[^{111}\text{In}]\text{InCl}_3$  (11 MBq) and 2 cycles of ultrafiltration ( $n = 3$ ). D) Analysis of  $^{111}\text{In}$ -HEGF release from  $[^{111}\text{In}]\text{In}$ -HEGF-Lip, with MB, with or without US application ( $n = 5$ ).  $p < 0.005$  by students unpaired two*

tailed *t*-test. Error bars represent standard deviation. Y axis on D represents % of 6.3 MBq loaded within the HEGF-lip of C.

#### *Passive loading of liposomes with HEGF*

The level and efficiency of HEGF loading into liposomes and the success of ultracentrifugation and SE centrifugation in removing free non-encapsulated HEGF was assessed using HPLC. 15% of the added HEGF was loaded into the liposomes. The dashed red lines in Figure 2B shows the peak at 18 min that is present in the profile for HEGF alone and the profile for HEGF-Lip but absent for control 'Empty Liposomes' to which no HEGF was added. This level of loading is in-line with that typically achieved by similar passive loading techniques[40]. This resulted in a peptide to lipid ratio of approximately 1:315 mg, considering lipid loss during cleaning. This is a limitation for all passive protein loading techniques which are inefficient because the liposomes cannot entrap 100% of the surrounding protein solution[41]. Cleaning techniques may also result in loss of the lipids. Importantly, the purification method employed in this study does allow the recovery and potential re-use of non-encapsulated HEGF[42]. The quantities of lipid and HEGF combined would be acceptable for human use if scaled-up based on calculations from Barenholz and Vallis *et al.*[11, 18].

#### *Indium-111 labelling of liposomes*


Having established that HEGF could be loaded into the liposomes the question of whether the internalised peptide could then be rapidly and efficiently radiolabelled with [<sup>111</sup>In]In<sup>3+</sup> was investigated. Figure 2C shows that of the 11 MBq of [<sup>111</sup>In]InCl<sub>3</sub> added to control empty liposomes (i.e. no HEGF), less than 1 MBq was retained after

washing. Similarly, when liposomes were loaded with HEGF and [ $^{111}\text{In}$ ]InCl<sub>3</sub> added before the non-encapsulated HEGF was removed by purification ('internal and external') the amount of radioactivity (2 MBq) was low (Supplementary Figure 5). This emphasises the need to remove free HEGF through purification after the passive loading step. In contrast when [ $^{111}\text{In}$ ]InCl<sub>3</sub> was added to purified HEGF liposomes >6 MBq (57%  $\pm$  10) of the [ $^{111}\text{In}$ ]In<sup>3+</sup> was encapsulated. Furthermore, >75% of the [ $^{111}\text{In}$ ]In<sup>3+</sup> remained incorporated after the liposomes were added to serum at 37°C for 5.5 h (Supplementary Figure 5D). When these purified products were analysed by SG-ITLC (Supplementary Figure 6) it was apparent that of the 1 MBq associated with the empty liposomes, 34% was incorporated. This radiolabelling is possible because [ $^{111}\text{In}$ ]InCl<sub>3</sub> can pass passively through the lipid shell, however, in the absence of HEGF, there is no mechanism to retain [ $^{111}\text{In}$ ]InCl<sub>3</sub> inside the liposome and so over time it can diffuse back out. In contrast, of the 6 MBq associated with HEGF-DTPA liposomes 93% remained at the SG-ITLC origin demonstrating efficient and robust incorporation within the liposomes.

To probe the nature of the [ $^{111}\text{In}$ ]In<sup>3+</sup> association with empty liposomes further, Triton X 100 was added to the empty liposomes and SG-ITLC analysis repeated (Supplementary Figure 7). Notably, post-Triton addition, 15% of the 1 MBq still remained at the origin. This suggests that a low level of [ $^{111}\text{In}$ ]InCl<sub>3</sub> interacts with the liposomal surface but is not internalised or retained. It is possible that this observation results from a transient interaction between the phosphate groups on the phospholipids of the liposome and the [ $^{111}\text{In}$ ]InCl<sub>3</sub>[43].

### Ultrasound stimulated release

[<sup>111</sup>In]In-HEGF-Lip were tested for US enhanced release in the presence of cavitating MBs. The amount [<sup>111</sup>In]In-HEGF that was released from liposomes that were exposed to MBs and US (i.e. cavitation) for 20 s was  $12 \pm 4\%$  of the total. In contrast, in the absence of cavitation only  $1.5 \pm 2\%$  of the cargo was released, as shown in Figure 2D. Graham *et al.* reported 20 – 30% release of doxorubicin from liposomes using a similar setup. Lentacker *et al.* reported ‘significant’ release of doxorubicin from liposomes attached to MBs and this resulted in a doubling of cell kill relative to liposomes that were not exposed to US[14, 44]. However, these examples may not be directly relevant as they concern the release of a drug (doxorubicin) with a much lower molecular weight than [<sup>111</sup>In]In-HEGF. The release of  $12 \pm 4\%$  of [<sup>111</sup>In]In-HEGF would be interesting to examine clinically in terms of the added cost of ultrasound relative to improvements in patient treatment to [<sup>111</sup>In]In-HEGF-Lip alone. Attachment of [<sup>111</sup>In]In-HEGF-Lip to MBs could improve release and therapeutic efficacy[45] but would also add complexity to the manufacture and purification process perhaps precluding facile synthesis in a hospital setting. Cavitation caused release of [<sup>111</sup>In]In-HEGF from the liposomes *in vitro*, but *in vivo* the ultrasound would also cause enhanced delivery[36] and improved endothelial opening[46] the combination of which is likely improve cost-to-benefit. It is important to note that whilst the *in vitro* experiments were limited to a 20 second ultrasound exposure time, *in vivo* experiments allow for replenishment of MBs and so longer exposure times on the order of minutes can occur. With regard to safety, recent research has shown that the observed extent of cavitation would have minimal impact on red blood cells [47].



543

544 Figure 3, Assessing delivery of  $[^{111}\text{In}]$ In-HEGF to cells in vitro. A) Counts per minute (CPM) per mg of  
 545 protein for MCF7 cells and MDA-MB-468 cells exposed to  $[^{111}\text{In}]$ In-HEGF-Lip and MBs with and without  
 546 US for 20 seconds, followed by incubation for 2 h ( $n = 3$ ;  $p > 0.05$ ; two tailed student's t test). B)  
 547 Examples of PCD power spectra averaged over the 20-second US exposure period for an empty dish  
 548 (control containing only media and no cells) and two cell lines with SV and  $[^{111}\text{In}]$ In-HEGF-Lip. Relative  
 549 to the control, the latter two spectra show elevated responses at integer and half-integer multiples of  
 550 the drive frequency (1.0 MHz) indicating nonlinear bubble vibration, along with broadband elevation  
 551 at all frequencies, suggesting bubble collapse. C) Comparison of colony survival for MDA-MB-468 cells;  
 552 controls, cells exposed to US only, MBs only, MBs and US,  $[^{111}\text{In}]$ In-HEGF-Lip and MBs,  $[^{111}\text{In}]$ In-HEGF-  
 553 Lip and MBs and US. D) Comparison of MCF7 cells following exactly the same exposure conditions ( $n =$   
 554 3).

*Cellular uptake.*

Cellular uptake of [<sup>111</sup>In]In-HEGF-Lip with and without US was measured after incubation of both cell lines for 2 h. A difference in uptake was noted to be dependent on US application, and not on receptor availability (Figure 3A). Incubation of MDA-MB-468 cells with [<sup>111</sup>In]In-HEGF-Lip, MBs and exposure to US gave an increase in CPM/mg of protein relative to cells exposed to [<sup>111</sup>In]In-HEGF-Lip and MBs but no US. The same finding was evident with MCF7 cells which have low expression of EGFR. No statistical difference between the uptake into the two cell lines when exposed to US was observed ( $P>0.05$ ). To exclude the possibility that interaction between MB cavitation and liposomes could be the cause of non-specific association with both cell lines, their exposure to liposomes and to cavitation events were temporally separated. Cells were incubated with [<sup>111</sup>In]In-HEGF-Lip, and a media change and wash performed after 2 h, followed by addition of MBs with or without US application. No difference in uptake was then observed with and without US (Supplementary Figure 8A and B). The results indicate that the US is not only causing release of [<sup>111</sup>In]In-HEGF as shown in Figure 2D but also potentially driving [<sup>111</sup>In]In-HEGF-Lip and released [<sup>111</sup>In]In-HEGF through the cell membrane into the cell cytoplasm regardless of cell EGFR density[48]. This is in accordance with a 'sonoporation' effect reported previously in several *in vitro* experiments[49-51]. To explore this further cell compartments were examined after 24 h (Supplementary Figure 9C) and showed that the signal for MDA-MB-468 cells was detected in the cytoplasm and the nucleus, whereas for MCF7 there is negligible signal detected in both fractions indicating the sonoporation has a transient effect for MCF7. There is also reduced exposure on the cell membrane. This agrees with mechanism of cytotoxicity for [<sup>111</sup>In]In-HEGF as reported by Reilly *et al.* which exploits the normal internalisation pathway for peptide



growth factors after their binding to cell surface receptors[6]. This pathway involves internalisation of growth factors and their receptors into cytoplasmic vesicles for proteolytic degradation and potential nuclear translocation[52]. The ultrasound causes liposomal release and increased uptake into cells regardless of cell receptor density, but for [<sup>111</sup>In]In-HEGF to have a cytotoxic impact it requires the pathway to nuclear transcription. This could possibly require a re-entry mechanism of [<sup>111</sup>In]In-HEGF and requires further exploration for the impact of ultrasound and nanoparticles on cellular uptake and cytotoxicity.

#### *Cell survival*

Using clonogenic assays it was shown that in the absence of [<sup>111</sup>In]In-HEGF-Lip the physical stimulus of US and addition of MBs, either alone or in combination, had minimal impact on cell survival in either cell line as the survival fraction (SF) was >85%. In contrast, [<sup>111</sup>In]In-HEGF-Lip were highly cytotoxic to MDA-MB-468 cells when used in combination with MBs and US. Whereas SF was maintained at 1 for all conditions in MCF7 cells SF was approximately 100-fold lower in MDA-MB-468 cells exposed to MB plus [<sup>111</sup>In]In-HEGF-Lip with US. (Figure 3C and D). Cavitation events triggered by MBs in the presence of US (Figure 3B) may cause release of [<sup>111</sup>In]In-HEGF from liposomes allowing receptor mediated uptake to take place. The *in vitro* data shown here and previous studies by Graham *et al*[14] indicate that uptake of released payload is likely to be occurring. However, the work of Lentacker *et al*[49] demonstrates that passage of the whole liposomes into cells is also a possibility. However, MBs with [<sup>111</sup>In]In-HEGF-lip and US only reduced the viability of EGFR overexpressing cells without impacting cells with minimal EGFR expression (Figure 3C and D).

Exposure of MDA-MB-468 cells to [<sup>111</sup>In]In-HEGF-Lip and MBs resulted in 80 ± 5% cell death even in the absence of US. One possible explanation for this observation is that liposome degradation of the liposomes occurred during the 24 h incubation at 37°C, with release of [<sup>111</sup>In]In-HEGF which only impacted MDA-MB-468 cells owing to higher EGFR expression.

Cavitation only occurred when MBs were present in solution at the time that US was applied (Figure 3B). No difference in toxicity was observed between MDA-MB-468 cells and MCF7 cells when MBs were cavitated in the presence of US but absence of [<sup>111</sup>In]In-HEGF-Lip (Figure 3C and D). The cavitation signal was highest during the first 1.5 s after which the cavitation signal markedly reduced by a factor of 4 - 6 and by an order of magnitude after 20 s (Supplementary Figure 9). It is possible that 20 s of US exposure is longer than required in this *in vitro* set-up.




Figure 4, Distribution and pharmacokinetics in a murine xenograft model in percentage of injected dose per gram (%ID/g), A) blood lifetime of  $[^{111}\text{In}]\text{In-HEGF-Lip}$  (red) and free  $[^{111}\text{In}]\text{In-HEGF}$  (blue) over 2 h from SPECT imaging (n=3), B) Biodistribution of free  $[^{111}\text{In}]\text{In-HEGF}$  (n = 4) and C)  $[^{111}\text{In}]\text{In-HEGF-Lip}$  (n=4) 24 h post injection, D) levels of radioactivity in the blood at 24 h from scintillation counting. (n=4) standard deviation shown, and E) Tumour uptake at 24 h with unpaired student t-test, \*\* =  $p < 0.005$ .

627

628 The [ $^{111}\text{In}$ ]In-HEGF-Lip were tested *in vivo* to examine biodistribution and  
629 pharmacokinetics. [ $^{111}\text{In}$ ]In-HEGF-Lip was shown to have an extended blood  
630 circulation time relative to free [ $^{111}\text{In}$ ]In-HEGF. As shown in Figure 4A the amount of  
631 [ $^{111}\text{In}$ ]In-HEGF decreased rapidly to  $0.1 \pm 0.1$  %ID/g within thirty minutes, whereas  
632 after 2 h,  $10 \pm 5$  %ID/g of liposomes were still present in the blood. However, the profile  
633 for the liposomes shows a rapid decrease over the course of the first ten minutes post  
634 injection (p.i.). The decay for [ $^{111}\text{In}$ ]In-HEGF was exponential with a blood half-life of  
635  $174 \text{ s} \pm 19 \text{ s}$ . The blood half-life for the [ $^{111}\text{In}$ ]In-HEGF-Lip was bi-exponential with a  
636 rapid phase,  $101 \text{ s} \pm 61 \text{ s}$ , followed by a slower phase  $\sim 50 \text{ min} \pm 19 \text{ min}$ . This is likely  
637 to represent a distribution phase followed by an elimination phase[53] but it may also  
638 be the consequence of release of up to 25% of the payload due to temperature and  
639 serum mediated destabilization (supplementary figure 5), or also possibly due to a  
640 small quantity of free [ $^{111}\text{In}$ ]In-HEGF which was not removed during the cleaning  
641 process. Notably, after 24 h [ $^{111}\text{In}$ ]In-HEGF-Lip is still detectable in the blood whereas  
642 [ $^{111}\text{In}$ ]In-HEGF is below detectable limits (Figure 4D).

643

644 [ $^{111}\text{In}$ ]In-HEGF-Lip results in a change in the 24 h biodistribution that differs from that  
645 of free [ $^{111}\text{In}$ ]In-HEGF. As shown in Figure 4B the majority of [ $^{111}\text{In}$ ]In-HEGF  
646 accumulated in the kidneys and liver whereas for the liposomal formulation (Figure  
647 4C) renal clearance reduced by half. Interestingly there is no increased signal in the  
648 liver for this liposomal construct, which was unexpected and different to other clinically  
649 available liposome formulations[53]. The biodistribution was also confirmed by 24 h  
650 SPECT images where signal for [ $^{111}\text{In}$ ]In-HEGF and [ $^{111}\text{In}$ ]In-HEGF-Lip is detectable  
651 in the kidneys and the liver (Supplementary Figure 10). Using scintillation counting of

organs *ex vivo*, most organs have double the amount of accumulated [ $^{111}\text{In}$ ]In $^{3+}$  when the liposomal formulation was used relative to the free radiopeptide. This effect was also evident in the tumour as the liposomal formulation delivered over twice the amount ( $2.2 \pm 0.5$  %ID/g) relative to free [ $^{111}\text{In}$ ]In-HEGF ( $0.8 \pm 0.2$  %ID/g) as shown in Figure 4E. The tumour to blood ratio was 1.77 for [ $^{111}\text{In}$ ]In-HEGF-Lip 24 h after injection, however, no ratio could be calculated for the  $^{111}\text{In}$ -HEGF because the quantity in the blood was negligible. The tumour to muscle ratio was  $3.15 \pm 1.8$  for the [ $^{111}\text{In}$ ]In-HEGF-Lip and  $5.69 \pm 2.4$  for [ $^{111}\text{In}$ ]In-HEGF 24h after injection but, these figures were not statistically different, indicating that [ $^{111}\text{In}$ ]In-HEGF-Lip is distributed more widely throughout the organs resulting in a higher background level. For [ $^{111}\text{In}$ ]In-HEGF-Lip at 24 h approximately 1 %ID/g remains in the blood and approximately 2 %ID/g is recovered from the tumour. There is a possibility that the blood load may over-estimate the level being assigned to tumour accumulation. However, it should be noted that the tumours are very poorly perfused (Supplementary Figure 11) and blood quantity in the tumour may be negligible. This is evidenced by the fact that at 20 min (when blood activity levels were 15 x higher than at 24 h) the tumour associated level without ultrasound (Figure 5A) was only 1%. However, the extended circulation time and the change in biodistribution are strikingly different for [ $^{111}\text{In}$ ]In-HEGF-Lip relative to [ $^{111}\text{In}$ ]In-HEGF alone. Further investigation of the role of the RES in the capture, degradation and excretion of the liposomes would be useful in understanding and optimising the PK of this formulation to allow further enhancements of passive and potentially active delivery to tumours.

The ~20% uptake in the kidneys from [ $^{111}\text{In}$ ]In-HEGF-Lip (Figure 5C) was unexpected even though it represents only half the amount observed for [ $^{111}\text{In}$ ]In-HEGF. One

possible explanation is slow release of the [<sup>111</sup>In]In-HEGF from inside the liposome over time. Another possibility is release of [<sup>111</sup>In]In-HEGF bound to the liposome surface over time. However, this is less likely because the liposomes are PEGylated and as such there are no potential binding sites for HEGF. Furthermore, the pharmacokinetic profile and biodistribution of the liposomes did not match those produced by a liposome formulation with externally bound [<sup>111</sup>In]In-HEGF[54] and there was no correlation of *in vitro* cellular uptake of [<sup>111</sup>In]In-HEGF-Lip and EGFR density (Figure 3A) which would be expected of liposomes with surface bound [<sup>111</sup>In]In-HEGF.

## Ultrasound enhanced delivery




Figure 5, US enhanced tumour uptake of  $[^{111}\text{In}]$ In-HEGF-Lip. A) Tumour uptake 20 minutes after injection of  $[^{111}\text{In}]$ In-HEGF-Lip, MBs comparing US to non-US treated tumours, unpaired student t-test  $p < 0.05$ ,  $n = 3$ , error bars represent standard deviations. B) Acoustic data collected during treatment providing validation of cavitation occurrence. C) Representative SPECT images of mouse tumour area after injection of  $[^{111}\text{In}]$ In-HEGF-Lip without US and D) with US. E) Autoradiography after 24 h examining distribution of indium within a tumour section following treatment with  $[^{111}\text{In}]$ In-HEGF-Lip and MBs or F)  $[^{111}\text{In}]$ In-HEGF-Lip and MBs and US (scale bar: 3 mm), G) contrast enhanced US image of a MDA-MB-468 tumour in an athymic nude mouse with MBs.

Having established that the  $[^{111}\text{In}]$ In-HEGF-Lip formulation provided more a favourable PK compared to free  $[^{111}\text{In}]$ In-HEGF, the impact of tumour directed US exposure on

the liposomes was studied. Intravenous [ $^{111}\text{In}$ ]In-HEGF-Lip and MB delivery to tumour (20 min p.i.) with the application of US was  $2.1 \pm 0.5$  %ID/g versus  $0.9 \pm 0.4$  %ID/g for [ $^{111}\text{In}$ ]In-HEGF-Lip and MBs alone ( $n = 3$ ,  $P < 0.05$ ). Cavitation was confirmed via PCD data (Figure 5B) specifically in the appearance of ultraharmonics (half integer multiples of the FUS frequency) and broadband noise which are well-known characteristics of nonlinear bubble behaviour in an US field[55]. In all US experiments with MBs, the total (ultraharmonic + broadband) cavitation level was at least five times greater than the root mean square background noise. Such acoustic feedback provides confidence that cavitation events occurred within the tumour at the time of liposome transition through the tumour vasculature. SPECT images of mice tumours taken at 20 min (Figure 5C and D) are consistent with enhanced tumour delivery, since signal intensity in the area of the tumour was greater following application of US compared to omission of US. Signal was noted immediately beyond the tumour, indicating that the area of US exposure was potentially more extensive than necessary. However, the clearly enhanced uptake observed in Figure 5 A and C versus D, does suggest that specific triggered release/delivery of a radiopharmaceutical from a liposomal carrier can be achieved *in vivo*. These results are in accordance with a previous report of delivery of a PET integrin tracer incorporated within a microbubble where focused US doubled tumour accumulation within 15 min in a human glioblastoma xenograft[56]. This result is likely a combination of liposome opening[14], enhanced delivery[36] and potential opening of the endothelial barrier[46], however which mechanism is dominant requires further investigation.



Notably, it is apparent that [<sup>111</sup>In]In-HEGF-Lip can also achieve similar (~2 %ID/g) tumour accumulation via simple passive means after 24 h (Figure 4E). In previous studies US has been shown to enhance the delivery of PLGA nanoparticles carrying microRNA miR-122 by 4 – 14 fold in human colon cancer xenografts in mice[57]. The reason for the lower increase reported here relative to this previous work is likely due to the poor vascularity of the tumour model and lack of penetration of MBs and [<sup>111</sup>In]In-HEGF-Lip to the tumour core. In Figure 5E and F autoradiography of the tumour sections show that although US-mediated cavitation increased the amount of liposomes deposited in the treated peripheral ‘ring’ of the tumour, the core has a low signal intensity regardless of the addition of US, indicating poor delivery beyond this perfused ring. There was no statistical difference in the penetration depth of liposomes with and without US. Contrast enhanced imaging also showed a low acoustic signal intensity within the tumour core (Figure 5G). The vascularity of the tumours was further examined via MRI and contrast enhanced US and compared with other tumour models (Supplementary Figure 11). The results showed that the MDA-MB-468 tumours are very poorly vascularised relative to a CT26 tumour model, which has been previously used for US enhanced delivery[58]. However, the CT26 tumour cell line is of murine origin and does not overexpress EGFR, making it an unsuitable model for our studies.

If the MBs cannot enter the tumour environment then it will not be possible for them to cavitate and enhance delivery and release of the [<sup>111</sup>In]In-HEGF-Lip. However, it is notable that even in a poorly vascularised tumour, MDA-MB-468, the application of US had a statistically significant impact on delivery, which might indicate therapeutic potential even for poorly vascularised tumours and requires further investigation. However, this outcome provides an important point to examine the vasculature of the

tumour line chosen in conjunction with a molecular target for enhancing delivery via US. Whether using this US approach to achieve rapid delivery of high peak intra-tumour concentration is therapeutically preferable to the slow prolonged delivery achieved by the EPR effect also requires further investigation. It is also possible cavitation within the tumour could also have an impact upon the vasculature causing potential changes and impacting repeat treatments. As such investigating tumour vasculature before and after treatment would be recommended in the future.

## Conclusion

This exploratory research has shown that radiopharmaceutical loaded nanoparticles combined with cavitation enhanced delivery does have clinical potential. Each stage requires optimisation and further investigation but the current strategy is relevant for radiopharmacies, only impacts cells overexpressing EGFR, has extended the circulation time, changed the biodistribution and increased tumour uptake warranting further study. This research also highlights potential pitfalls such as the impact of vasculature on US enhanced delivery which is another key variable for tumour target selection along with target receptor/antigen presentation.

## Limitations

As this research combined existing technologies minimal characterisation was performed for the nanoparticles and the radiotherapeutic which have been examined in previous publications. Further characterisation/optimisation of the loading techniques and the nanoparticles will be required before progressing to other

experiments. Notably optimising radiolabelling to remove the SE centrifugation, which will not be desirable in a radiopharmacy. Use of physical stimuli to deliver therapeutics must overcome physical barriers in the human body. Xenograft tumours in a mouse model are likely to be different morphologically from human tumours and certainly in terms of access for US. Development of *ex vivo* models replicating physical conditions found within the human body may be a means to more accurately assess US enhanced delivery of radiopharmaceuticals for a clinical setting. Further improvements in cavitation assisted delivery may potentially be realised through optimisation of US exposure conditions paired with model-specific perfusion analysis. Improved matching of the pharmacokinetics of the liposomes with agents used to seed cavitation may help sustain and improve the delivery over longer periods, i.e. the replacement of MBs with polymeric nanocups described by Myers et al[59], a formulation which nucleates cavitation over an extended period.

## References

- [1] M.R. Gill, N. Falzone, Y. Du, K.A. Vallis, Targeted radionuclide therapy in combined-modality regimens, *The Lancet Oncology*, 18 (2017) e414-e423.
- [2] J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O'Dorisio, R.P. Baum, H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J.L. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning, Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine Tumors, *New England Journal of Medicine*, 376 (2017) 125-135.
- [3] M. Boegemann, A.J. Schrader, K. Rahbar, <sup>177</sup>Lu-PSMA-Therapie, *Der Urologe*, 56 (2017) 1440-1444.
- [4] B. Cornelissen, K.A. Vallis, Targeting the nucleus: an overview of Auger-electron radionuclide therapy, *Current drug discovery technologies*, 7 (2010).
- [5] J.V. Leyton, M.D. Hu, C. Gao, P.V. Turner, J.E. Dick, M. Minden, R.M. Reilly, Auger Electron Radioimmunotherapeutic Agent Specific for the CD123(+)/CD131(-) Phenotype of the Leukemia Stem Cell Population, *Journal of Nuclear Medicine*, 52 (2011) 1465-1473.

824 [6] R.M. Reilly, P. Chen, J. Wang, D. Scollard, R. Cameron, K.A. Vallis, Preclinical  
825 pharmacokinetic, biodistribution, toxicology, and dosimetry studies of In-111-DTPA-human  
826 epidermal growth factor: An Auger electron-emitting radiotherapeutic agent for epidermal  
827 growth factor receptor-positive breast cancer, *Journal of Nuclear Medicine*, 47 (2006) 1023-  
828 1031.

829 [7] P. Lai, W. Daear, R. Löbenberg, E.J. Prenner, Overview of the preparation of organic  
830 polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly(d,l-lactide-co-  
831 glycolic acid) and polyalkylcyanoacrylate, *Colloids and Surfaces B: Biointerfaces*, 118 (2014)  
832 154-163.

833 [8] A.Z. Wang, K. Yuet, L.F. Zhang, F.X. Gu, M. Huynh-Le, A.F. Radovic-Moreno, P.W. Kantoff,  
834 N.H. Bander, R. Langer, O.C. Farokhzad, ChemoRad nanoparticles: a novel multifunctional  
835 nanoparticle platform for targeted delivery of concurrent chemoradiation, *Nanomedicine*, 5  
836 (2010) 361-368.

837 [9] E. Vegt, M. Melis, A. Eek, M. de Visser, M. Brom, W.J.G. Oyen, M. Gotthardt, M. de Jong,  
838 O.C. Boerman, Renal uptake of different radiolabelled peptides is mediated by megalin:  
839 SPECT and biodistribution studies in megalin-deficient mice, *European journal of nuclear*  
840 *medicine and molecular imaging*, 38 (2011) 623-632.

841 [10] L. Song, N. Falzone, K.A. Vallis, EGF-coated gold nanoparticles provide an efficient nano-  
842 scale delivery system for the molecular radiotherapy of EGFR-positive cancer, *International*  
843 *Journal of Radiation Biology*, 92 (2016) 716-723.

844 [11] K.A. Vallis, R.M. Reilly, D. Scollard, P. Merante, A. Brade, S. Velauthapillai, C. Caldwell, I.  
845 Chan, M. Freeman, G. Lockwood, N.A. Miller, B. Cornelissen, J. Petronis, K. Sabate, Phase I  
846 trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of  
847 (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive  
848 breast cancer, *American journal of nuclear medicine and molecular imaging*, 4 (2014) 181-  
849 192.

850 [12] G. Milano, J.P. Spano, B. Leyland-Jones, EGFR-targeting drugs in combination with  
851 cytotoxic agents: From bench to bedside, a contrasted reality, *British Journal of Cancer*, 99  
852 (2008) 1-5.

853 [13] F. Danhier, O. Feron, V. Préat, To exploit the tumor microenvironment: Passive and  
854 active tumor targeting of nanocarriers for anti-cancer drug delivery, *Journal of Controlled*  
855 *Release*, 148 (2010) 135-146.

856 [14] S.M. Graham, R. Carlisle, J.J. Choi, M. Stevenson, A.R. Shah, R.S. Myers, K. Fisher, M.-B.  
857 Peregrino, L. Seymour, C.C. Coussios, Inertial cavitation to non-invasively trigger and  
858 monitor intratumoral release of drug from intravenously delivered liposomes, *Journal of*  
859 *Controlled Release*, 178 (2014) 101-107.

860 [15] S.D. Li, L. Huang, Pharmacokinetics and biodistribution of nanoparticles, *Molecular*  
861 *Pharmaceutics*, 5 (2008) 496-504.

862 [16] H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the  
863 EPR effect in macromolecular therapeutics: A review, *Journal of Controlled Release*, 65  
864 (2000) 271-284.

865 [17] S. Wilhelm, A.J. Tavares, Q. Dai, S. Ohta, J. Audet, H.F. Dvorak, W.C.W. Chan, Analysis of  
866 nanoparticle delivery to tumours, *Nature Reviews Materials*, 1 (2016) 16014.

867 [18] Y. Barenholz, Doxil® - The first FDA-approved nano-drug: Lessons learned, *Journal of*  
868 *Controlled Release*, 160 (2012) 117-134.

869 [19] T.M. Allen, P.R. Cullis, Liposomal drug delivery systems: From concept to clinical  
870 applications, *Advanced Drug Delivery Reviews*, 65 (2013) 36-48.

871 [20] D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.D.  
872 Lee, M.C. Woodle, D.D. Lasic, C. Redemann, F.J. Martin, Sterically stabilized liposomes:  
873 Improvements in pharmacokinetics and antitumor therapeutic efficacy, *Proceedings of the*  
874 *National Academy of Sciences of the United States of America*, 88 (1991) 11460-11464.

875 [21] L.D. Mayer, M.B. Bally, P.R. Cullis, Uptake of adriamycin into large unilamellar vesicles  
876 in response to a pH gradient, *Biochimica et Biophysica Acta (BBA) - Biomembranes*, 857  
877 (1986) 123-126.

878 [22] U. Pick, Liposomes with a large trapping capacity prepared by freezing and thawing of  
879 sonicated phospholipid mixtures, *Archives of Biochemistry and Biophysics*, 212 (1981) 186-  
880 194.

881 [23] O.C. Boerman, G. Storm, W.J.G. Oyen, L. Van Bloois, J.W.M. Van der Meer, R.A.M.J.  
882 Claessens, D.J.A. Crommelin, F.H.M. Corstens, Sterically stabilized liposomes labeled with  
883 Indium-111 to image focal infection, *Journal of Nuclear Medicine*, 36 (1995) 1639-1644.

884 [24] M.R. Lewis, R. Kannan, Development and applications of radioactive nanoparticles for  
885 imaging of biological systems, *Wiley Interdisciplinary Reviews: Nanomedicine and*  
886 *Nanobiotechnology*, 6 (2014) 628-640.

887 [25] P.L. Beaumier, K.J. Hwang, An efficient method for loading Indium-111 into liposomes  
888 using acetylacetone, *Journal of Nuclear Medicine*, 23 (1982) 810-815.

889 [26] K.J. Hwang, J.E. Merriam, P.L. Beaumier, K.F.S. Luk, Encapsulation, with high efficiency,  
890 of radioactive metal ions in liposomes, *BBA - General Subjects*, 716 (1982) 101-109.

891 [27] L.D.G. Mota, A.L.B. De Barros, L.L. Fuscaldi, M.C. De Oliveira, V.N. Cardoso, Long-  
892 circulating and pH-sensitive liposome preparation trapping a radiotracer for inflammation  
893 site detection, *Journal of Nanoscience and Nanotechnology*, 15 (2015) 4149-4158.

894 [28] B. Goins, R. Klipper, A.S. Rudolph, R.O. Cliff, R. Blumhardt, W.T. Phillips, Biodistribution  
895 and imaging studies of technetium-99m-labeled liposomes in rats with focal infection,  
896 *Journal of Nuclear Medicine*, 34 (1993) 2160-2168.

897 [29] T.H. Chow, Y.Y. Lin, J.J. Hwang, H.E. Wang, Y.L. Tseng, V.F. Pang, S.J. Wang, J. Whang-  
898 Peng, G. Ting, Diagnostic and therapeutic evaluation of <sup>111</sup>In-vinorelbine-liposomes in a  
899 human colorectal carcinoma HT-29/luc-bearing animal model, *Nuclear Medicine and*  
900 *Biology*, 35 (2008) 623-634.

901 [30] D.S. Ferreira, F.A. Boratto, V.N. Cardoso, R. Serakides, S.O. Fernandes, L.A.M. Ferreira,  
902 M.C. Oliveira, Alendronate-coated long-circulating liposomes containing <sup>99m</sup>technetium-  
903 ceftizoxime used to identify osteomyelitis, *International Journal of Nanomedicine*, 10 (2015)  
904 2441-2450.

905 [31] A.I. Jensen, G.W. Severin, A.E. Hansen, F.P. Fliedner, R. Eliassen, L. Parhamifar, A. Kjær,  
906 T.L. Andresen, J.R. Henriksen, Remote-loading of liposomes with manganese-52 and in vivo  
907 evaluation of the stabilities of <sup>52</sup>Mn-DOTA and <sup>64</sup>Cu-DOTA using radiolabelled liposomes  
908 and PET imaging, *Journal of Controlled Release*, 269 (2018) 100-109.

909 [32] J.R. Henriksen, A.L. Petersen, A.E. Hansen, C.G. Frankær, P. Harris, D.R. Elema, A.T.  
910 Kristensen, A. Kjær, T.L. Andresen, Remote Loading of <sup>64</sup>Cu<sup>2+</sup> into Liposomes without the  
911 Use of Ion Transport Enhancers, *ACS Applied Materials & Interfaces*, 7 (2015) 22796-22806.

912 [33] M. Rotman, M.M. Welling, A. Bunschoten, M.E. de Backer, J. Rip, R.J.A. Nabuurs, P.J.  
913 Gaillard, M.A. van Buchem, S.M. van der Maarel, L. van der Weerd, Enhanced glutathione  
914 PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a  
915 mouse model for Alzheimer's disease, *J Control Release*, 203 (2015) 40-50.

- [34] S. Sofou, B.J. Kappel, J.S. Jaggi, M.R. McDevitt, D.A. Scheinberg, G. Sgouros, Enhanced retention of the  $\alpha$ -particle-emitting daughters of actinium-225 by liposome carriers, *Bioconjugate Chem.*, 18 (2007) 2061-2067.
- [35] E. Quaia, *Contrast Media in Ultrasonography*, 2005.
- [36] R. Carlisle, J. Choi, M. Bazan-Peregrino, R. Laga, V. Subr, L. Kostka, K. Ulbrich, C.C. Coussios, L.W. Seymour, Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound, *Journal of the National Cancer Institute*, 105 (2013) 1701-1710.
- [37] R. Myers, M. Grundy, C. Rowe, C.M. Coviello, L. Bau, P. Erbs, J. Foloppe, J.-M. Balloul, C. Story, C.C. Coussios, R. Carlisle, Ultrasound-mediated cavitation does not decrease the activity of small molecule, antibody or viral-based medicines, *International Journal of Nanomedicine*, 13 (2018) 337-349.
- [38] R.M. Reilly, J. Gariépy, Factors Influencing the Sensitivity of Tumor Imaging with a Receptor-Binding Radiopharmaceutical, *Journal of Nuclear Medicine*, 39 (1998) 1036-1043.
- [39] M. Maji, S. Mazumder, S. Bhattacharya, S.T. Choudhury, A. Sabur, M. Shadab, P. Bhattacharya, N. Ali, A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8(+) T Cells, *Scientific reports*, 6 (2016) 27206-27206.
- [40] J.-P. Colletier, B. Chaize, M. Winterhalter, D. Fournier, Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer, *BMC Biotechnology*, 2 (2002) 9-9.
- [41] A. Akbarzadeh, R. Rezaei-Sadabady, S. Davaran, S.W. Joo, N. Zarghami, Y. Hanifehpour, M. Samiei, M. Kouhi, K. Nejati-Koshki, Liposome: classification, preparation, and applications, *Nanoscale Research Letters*, 8 (2013) 102-102.
- [42] J.C. Giddings, F.J. Yang, M.N. Myers, Flow field-flow fractionation as a methodology for protein separation and characterization, *Analytical Biochemistry*, 81 (1977) 395-407.
- [43] R.E. Weiner, Role of Phosphate-Containing Compounds in the Transfer of Indium-111 and Gallium-67 from Transferrin to Ferritin, *Journal of Nuclear Medicine*, 30 (1989) 70-79.
- [44] I. Lentacker, B. Geers, J. Demeester, S.C. De Smedt, N.N. Sanders, Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: Cytotoxicity and mechanisms involved, *Molecular Therapy*, 18 (2010) 101-108.
- [45] B. Geers, I. Lentacker, N.N. Sanders, J. Demeester, S. Meairs, S.C. De Smedt, Self-assembled liposome-loaded microbubbles: The missing link for safe and efficient ultrasound triggered drug-delivery, *Journal of Controlled Release*, 152 (2011) 249-256.
- [46] A. Bouakaz, A. Zeghimi, A.A. Doinikov, Sonoporation: Concept and mechanisms, in: *Advances in Experimental Medicine and Biology*, 2016, pp. 175-189.
- [47] C. Mannaris, L. Bau, M. Grundy, M. Gray, H. Lea-Banks, A. Seth, B. Teo, R. Carlisle, E. Stride, C.C. Coussios, Microbubbles, Nanodroplets and Gas-Stabilizing Solid Particles for Ultrasound-Mediated Extravasation of Unencapsulated Drugs: An Exposure Parameter Optimization Study, *Ultrasound Med. Biol.*, 45 (2019) 954-967.
- [48] Y. Hu, J.M.F. Wan, A.C.H. Yu, Membrane Perforation and Recovery Dynamics in Microbubble-Mediated Sonoporation, *Ultrasound Med. Biol.*, 39 (2013) 2393-2405.
- [49] I. Lentacker, S.C. De Smedt, J. Demeester, V. Van Marck, M. Bracke, N.N. Sanders, Lipoplex-loaded microbubbles for gene delivery: A trojan horse controlled by ultrasound, *Advanced Functional Materials*, 17 (2007) 1910-1916.

- [50] I. Lentacker, I. De Cock, R. Deckers, S.C. De Smedt, C.T.W. Moonen, Understanding ultrasound induced sonoporation: Definitions and underlying mechanisms, *Advanced Drug Delivery Reviews*, 72 (2014) 49-64.
- [51] E. Stride, C. Porter, A.G. Prieto, Q. Pankhurst, Enhancement of Microbubble Mediated Gene Delivery by Simultaneous Exposure to Ultrasonic and Magnetic Fields, *Ultrasound in Medicine & Biology*, 35 (2009) 861-868.
- [52] R.M. Reilly, R. Kiarash, R.G. Cameron, N. Porlier, J. Sandhu, R.P. Hill, K. Vallis, A. Hendler, J. Gariépy, <sup>111</sup>In-Labeled EGF Is Selectively Radiotoxic to Human Breast Cancer Cells Overexpressing EGFR, *Journal of Nuclear Medicine*, 41 (2000) 429-438.
- [53] A. Gabizon, H. Shmeeda, Y. Barenholz, Pharmacokinetics of Pegylated Liposomal Doxorubicin, *Clinical Pharmacokinetics*, 42 (2003) 419-436.
- [54] E. Thomas, J.U. Menon, J. Owen, I. Skaripa-Koukelli, S. Wallington, M. Gray, C. Mannaris, V. Kersemans, D. Allen, P. Kinchesh, S. Smart, R. Carlisle, K.A. Vallis, Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy, *Theranostics*, 9 (2019) 5595-5609.
- [55] C.D. Arvanitis, M. Bazan-Peregrino, B. Rifai, L.W. Seymour, C.C. Coussios, Cavitation-Enhanced Extravasation for Drug Delivery, *Ultrasound Med. Biol.*, 37 (2011) 1838-1852.
- [56] Y.-H. Chung, P.-H. Hsu, C.-W. Huang, W.-C. Hsieh, F.-T. Huang, W.-C. Chang, H. Chiu, S.-T. Hsu, T.-C. Yen, Evaluation of Prognostic Integrin  $\alpha 2\beta 1$  PET Tracer and Concurrent Targeting Delivery Using Focused Ultrasound for Brain Glioma Detection, *Molecular Pharmaceutics*, 11 (2014) 3904-3914.
- [57] T.Y. Wang, J.W. Choe, K. Pu, R. Devulapally, S. Bachawal, S. Machtaler, S.M. Chowdhury, R. Luong, L. Tian, B. Khuri-Yakub, J. Rao, R. Paulmurugan, J.K. Willmann, Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer, *Journal of Controlled Release*, 203 (2015) 99-108.
- [58] J.J. Kwan, R. Myers, C.M. Coviello, S.M. Graham, A.R. Shah, E. Stride, R.C. Carlisle, C.C. Coussios, Ultrasound-Propelled Nanocups for Drug Delivery, *Small (Weinheim an der Bergstrasse, Germany)*, 11 (2015) 5305-5314.
- [59] R. Myers, C. Coviello, P. Erbs, J. Foloppe, C. Rowe, J. Kwan, C. Crake, S. Finn, E. Jackson, J.-M. Balloul, C. Story, C. Coussios, R. Carlisle, Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus, *Molecular Therapy*, 24 (2016) 1627-1633.

